Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI

Melchardt, Thomas; Troppan, Katharina; Weiß, Lukas; Hufnagl, Clemens; Neureiter, Daniel; Tränkenschuh, Wolfgang; Schlick, Konstantin; Huemer, Florian; Deutsch, Alexander; Neumeister, Peter; Greil, Richard; Pichler, Martin; Egle, Alexander

doi:10.6004/jnccn.2015.0178

Cited by 30 publications

(44 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies[25–27] were found to be eligible through updated searching. In total, 9 studies [12, 13, 17, 18, 25–29] with 2297 patients were included for the meta-analysis. The main characteristics of included studies are demonstrated in Table 1.…”

Section: Resultsmentioning

confidence: 99%

“…Seven studies[12, 13, 17, 18, 25–27] were published in English and 2 studies [28, 29] were published in Chinese. Eight studies [12, 13, 17, 18, 26–29] investigated the association between NLR and OS and 7 studies [12, 17, 18, 25–27, 29] reported a connection between NLR and PFS. All studies obtained a NOS score of ≥7.…”

Section: Resultsmentioning

confidence: 99%

“…A series of prognostic indexes based on laboratory test results have emerged as objective and inexpensive indicators [9]. Such parameters include C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and modified Glasgow Prognostic Score (mGPS)[10–15], of which, NLR was found to be related with worse survival outcomes in a variety of tumors [16], including DLBCL [12, 13, 17, 18]. However, previous studies have reported controversial results concerning the prognostic value of NLR in DLBCL [12, 17–20].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis

Wang

Liu

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundNeutrophil-to-lymphocyte ratio (NLR) has been investigated as a prognostic marker in patients with diffuse large B-cell lymphoma (DLBCL); however, the results remain controversial. This study aimed to explore the association between NLR and survival outcomes and clinicopathological factors in DLBCL.MethodsRelevant studies were retrieved by searching PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) databases. The last search was updated on February 17, 2017. Hazard ratios (HRs) and odds ratios (ORs) and their 95% confidence intervals (CIs) were used as effective measures in the meta-analysis. Random-effects models and fixed-effects models were used for analyses. Meta-regression was performed. Publication bias was assessed using Begg’s test. Stata version 12.0 was used for all analyses.ResultsA total of 9 studies with 2297 patients were included in the meta-analysis. The pooled results showed that NLR was a significant indicator for poor overall survival (OS) (HR = 1.84, 95% CI = 1.52–2.22, p<0.001) and poor progression-free survival (PFS) (HR = 1.64, 95% CI = 1.36–1.98, p<0.001). NLR remained a significant biomarker for OS and PFS regardless of location, sample size or cut-off value. In addition, high NLR was also associated with Ann Arbor stage (OR = 2.09, 95% CI = 1.14–3.81, p = 0.017), lactate dehydrogenase level (OR = 2.74, 95% CI = 1.16–6.46, p = 0.021), extranodal disease (OR = 1.63, 95% CI = 1.06–2.52, p = 0.027), and International Prognostic Index score (OR = 2.44, 95% CI = 1.03–5.08, p = 0.043). However, NLR was found to have no significant association with sex (OR = 0.89, 95% CI = 0.71–1.11, p = 0.29), age (OR = 1.18, 95% CI = 0.94–1.48, p = 0.152), European Cooperative Oncology Group performance status score (OR = 1.78, 95% CI = 0.71–4.46, p = 0.217), or presence of B symptoms (OR = 1.56, 95% CI = 0.7–3.48, p = 0.278).ConclusionIn conclusion, our meta-analysis demonstrated that NLR has a strong association with worse OS and PFS in patients with DLBCL. NLR could be recommended as an inexpensive prognostic biomarker in DLBCL.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis

Wang

Liu

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Low serum albumin and low BMI are frequent findings in patients with advanced malignancy, and can be considered as proxy variables for poor performance status and cancer-associated cachexia/anorexia [4,5]. A combination of these variables, such as the ALI, may lead to a more refined outcome prediction as compared to using these variables individually, although no study to date has provided support for this hypothesis in a statistically stringent fashion.…”

mentioning

confidence: 99%

“…First, the concept of outcome prediction in DLBCL patients using blood-based biomarkers such as neutrophil and lymphocyte counts, C-reactive protein, and albumin is not new [4]. Low serum albumin and low BMI are frequent findings in patients with advanced malignancy, and can be considered as proxy variables for poor performance status and cancer-associated cachexia/anorexia [4,5].…”

mentioning

confidence: 99%

Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores?

Posch

Pichler²

2017

Acta Haematol

Self Cite

View full text Add to dashboard Cite

A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma

et al. 2020

View full text Add to dashboard Cite

Background Although various prognostic models for primary central nervous system lymphoma (PCNSL) have been developed, there is no consensus regarding the optimal prognostic index. We aimed to evaluate potential prognostic factors and construct a novel predictive model for PCNSL patients. Methods We enrolled newly diagnosed PCNSL patients between 2003 and 2015. The primary endpoint was progression‐free survival (PFS), and the secondary endpoint was overall survival (OS). The prognostic factors identified using multivariate Cox proportional hazards models were used to develop a predictive model. We subsequently validated the prognostic model in an independent cohort. We also evaluated the validity of the existing scores: the International Extranodal Lymphoma Study Group (IELSG), the Nottingham/Barcelona (NB), and the Memorial Sloan‐Kettering Cancer Center models (MSKCC). Results We identified 101 patients with newly diagnosed PCNSL at our center. Multivariate analysis showed that age ≥80, deep brain lesions, and ECOG ≥2 were independent risk factors of PFS. Assigning one point for each factor, we constructed a novel prognostic model, the Taipei Score, with four distinct risk groups (0‐3 points). The performances of the Taipei Score in discriminating both PFS and OS in the training cohort were significant, and the score was validated in the external validation cohort. The IELSG, NB and MSKCC models had insufficient discriminative ability for either PFS or OS in both cohorts. Conclusion The Taipei Score is a simple model that discriminates PFS and OS for PCNSL patients. The score may offer disease risk stratification and facilitate clinical decision‐making.

show abstract

Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI

Cited by 30 publications

References 34 publications

Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis

Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: A meta-analysis

Inflammatory Biomarkers in Diffuse Large B-Cell Lymphoma: Time for Extending the Established Prognosis Scores?

A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma

Contact Info

Product

Resources

About